Literature DB >> 28126271

Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections.

Sanjeev Mariathasan1, Man-Wah Tan2.   

Abstract

Antibodies are potent components of the immune repertoire and have been successfully exploited to treat bacterial infections. Recently an antibody-antibiotic conjugate (AAC) that combines key attributes of an antibody and antibiotic has been shown to be efficacious against Staphylococcus aureus infection. An AAC has three components: an antibiotic payload to kill bacteria, an antibody to target delivery of the payload to bacteria, and a linker attaching the payload to the antibody. With increasing understanding of the biology and pathophysiology of S. aureus, this article highlights how this knowledge has led to the design principles of an efficacious AAC, and discusses how the AAC platform could be translationally applied to treat other perilous infectious diseases.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28126271     DOI: 10.1016/j.molmed.2016.12.008

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  30 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  Determining the immunological characteristics of a novel human monoclonal antibody developed against staphylococcal enterotoxin B.

Authors:  Yuanyuan Liu; Zhen Song; Shuang Ge; Jinyong Zhang; Limin Xu; Feng Yang; Dongshui Lu; Ping Luo; Jiang Gu; Quanming Zou; Hao Zeng
Journal:  Hum Vaccin Immunother       Date:  2020-04-10       Impact factor: 3.452

Review 3.  Recalcitrant Staphylococcus aureus Infections: Obstacles and Solutions.

Authors:  Sarah E Rowe; Jenna E Beam; Brian P Conlon
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

4.  Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against Staphylococcus aureus.

Authors:  Rong Deng; Chenguang Zhou; Dongwei Li; Hao Cai; Siddharth Sukumaran; Montserrat Carrasco-Triguero; Ola Saad; Denise Nazzal; Christopher Lowe; Saroja Ramanujan; Amrita V Kamath
Journal:  MAbs       Date:  2019-06-20       Impact factor: 5.857

Review 5.  Anti-bacterial monoclonal antibodies: next generation therapy against superbugs.

Authors:  Hui Wang; Daijie Chen; Huili Lu
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-01       Impact factor: 4.813

6.  Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model.

Authors:  Shun Xin Wang-Lin; Chenguang Zhou; Amrita V Kamath; Kyu Hong; Neelima Koppada; Ola M Saad; Montserrat Carrasco-Triguero; Cyrus Khojasteh; Rong Deng
Journal:  MAbs       Date:  2018-08-06       Impact factor: 5.857

7.  Inhibitory effects of aptamer targeted teicoplanin encapsulated PLGA nanoparticles for Staphylococcus aureus strains.

Authors:  Samet Ucak; Mert Sudagidan; Baris A Borsa; Banu Mansuroglu; Veli C Ozalp
Journal:  World J Microbiol Biotechnol       Date:  2020-04-25       Impact factor: 3.312

8.  Platform to Discover Protease-Activated Antibiotics and Application to Siderophore-Antibiotic Conjugates.

Authors:  Jonathan H Boyce; Bobo Dang; Beatrice Ary; Quinn Edmondson; Charles S Craik; William F DeGrado; Ian B Seiple
Journal:  J Am Chem Soc       Date:  2020-12-10       Impact factor: 15.419

Review 9.  Monoclonal Antibodies Targeting Surface-Exposed and Secreted Proteins from Staphylococci.

Authors:  Pietro Speziale; Giampiero Pietrocola
Journal:  Vaccines (Basel)       Date:  2021-05-04

10.  PEGylated Oligothioetheramide Prodrugs Activated by Host Serum Proteases.

Authors:  Christine M Artim; Manisha Kunala; Meghan K O'Leary; Christopher A Alabi
Journal:  Chembiochem       Date:  2021-07-13       Impact factor: 3.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.